Development
e-therapeutics plc
ETXPF
OTC PK
| 07/31/2023 | 04/30/2023 | 01/31/2023 | 10/31/2022 | 07/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -43.94% | -49.87% | -- | -- | -45.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -43.94% | -49.87% | -- | -- | -45.75% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -43.94% | -49.87% | -- | -- | -45.75% |
| SG&A Expenses | 8.12% | -3.30% | -35.79% | -39.99% | 3.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.99% | 35.94% | -13.16% | -18.84% | 6.83% |
| Operating Income | -58.20% | -41.49% | 15.82% | 21.33% | -13.99% |
| Income Before Tax | -51.64% | -35.63% | 22.15% | 27.24% | -14.57% |
| Income Tax Expenses | -51.21% | -35.25% | 8.73% | 14.68% | 7.60% |
| Earnings from Continuing Operations | -51.72% | -35.70% | 24.12% | 29.08% | -19.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.72% | -35.70% | 24.12% | 29.08% | -19.92% |
| EBIT | -58.20% | -41.49% | 15.82% | 21.33% | -13.99% |
| EBITDA | -60.58% | -43.63% | 16.31% | 22.74% | -9.30% |
| EPS Basic | -35.56% | -20.41% | 37.66% | 41.77% | -18.42% |
| Normalized Basic EPS | -35.29% | -22.22% | 36.36% | 39.29% | -17.24% |
| EPS Diluted | -35.56% | -20.41% | 37.66% | 41.77% | -18.42% |
| Normalized Diluted EPS | -35.29% | -22.22% | 36.36% | 39.29% | -17.24% |
| Average Basic Shares Outstanding | 11.95% | 11.95% | 21.54% | 21.54% | -0.22% |
| Average Diluted Shares Outstanding | 11.95% | 11.95% | 21.54% | 21.54% | -0.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |